A new large-scale study has mapped the first molecular events that drive the formation of harmful amyloid protein aggregates ...

(9) The assays were selected from a commercial NovaScreen panel (NVS) for preclinical drug development. These assays measure chemical binding to nuclear receptors, G-protein-coupled receptors (GPCR), ...